It is the target date by which the FDA aims to complete its review of a drug application. It is a decision deadline, not a promise of approval, and the date can be extended.
PDUFA stands for the Prescription Drug User Fee Act. Under it, drug companies pay fees to the FDA, and in exchange the agency commits to reviewing applications within set timeframes.
The PDUFA date is the target the agency has set for a particular application. It is a scheduling commitment, not a verdict.
A standard review targets roughly ten months. Priority Review targets roughly six, and is granted where the treatment could be a significant improvement over what already exists.
Priority Review says the FDA considers the application important enough to look at sooner. It is not a signal about the outcome.
The FDA may approve the application, approve it with a narrower label than requested, or issue a Complete Response Letter setting out what would be needed for approval.
The date can also move. The agency may extend the review — often by three months — if substantial new information is submitted.
Some applications are for a brand new medicine. Others are supplemental: the drug is already approved, and the company is asking to use it for an additional condition or in combination with something else.
The distinction matters, because a supplemental application is about how large the market for an existing product becomes — not about whether the product exists.
One question, no account: what did you come here for, and did you find it? A person reads these, and they shape what gets written next.
From StockMotive — the honest why behind every market move. Educational information only, not investment advice.